RM-CVS / Coagulation and vascular signalling
Icatibant
Also known as: Icatibant acetate · Firazyr · HOE 140
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Icatibant is a synthetic peptide antagonist of the bradykinin B2 receptor.
Evidence position
The regulated prefilled-syringe record supports Grade A for that product.
What the record does not establish
The label is not a test of a detached sample and does not transfer to another formulation.
Sources
- 01Firazyr prescribing informationDailyMed / U.S. National Library of Medicine
- Shows
- Current U.S. label for a defined icatibant acetate injection
- Does not show
- Does not authenticate another salt, concentration, container or source
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Icatibant
- CID
- 6918173
- Formula
- C59H89N19O13S
- Mass
- 1304.5
PUBMED / FOUND RECORDS
- [Angioedema].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete / 2007 DecPMID 18004529 / DOI 10.1007/s00105-007-1440-8
- Icatibant. / 2006PMID 36940272
- [Acquired angioedema].Presse medicale (Paris, France : 1983) / 2015 JanPMID 25535166 / DOI 10.1016/j.lpm.2014.09.010
- The Angiotensin-Converting-Enzyme-Induced Angioedema.Immunology and allergy clinics of North America / 2017 FebPMID 27886906 / DOI 10.1016/j.iac.2016.08.011
- ACE inhibitor-mediated angioedema.International immunopharmacology / 2020 JanPMID 31835086 / DOI 10.1016/j.intimp.2019.106081
CLINICALTRIALS.GOV / FOUND RECORDS
- Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced AngioedemaCOMPLETED / PHASE3 / ShireNCT01919801 / DIRECT intervention MATCH: Icatibant
- Inhibition of Bradykinin in COVID-19 Infection With IcatibantCOMPLETED / PHASE2, PHASE3 / Belfast Health and Social Care TrustNCT05407597 / DIRECT intervention MATCH: Icatibant
- A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE AttacksCOMPLETED / NO PHASE / KalVista Pharmaceuticals, Ltd.NCT07009262 / DIRECT title MATCH: Icatibant
- Bradykinin Receptor Antagonism During Cardiopulmonary BypassCOMPLETED / PHASE2, PHASE3 / Vanderbilt UniversityNCT00223704 / DIRECT intervention MATCH: Icatibant
- A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary AngioedemaCOMPLETED / PHASE3 / ShireNCT01386658 / DIRECT intervention MATCH: Icatibant